Yu Jianjun, the co-founder and chief executive of podcast start-up Ximalaya FM. The company's product suite includes a digital continuous care platform for patients with critical diseases, an AI-enabled curation system for longitudinal medical data, and a precision life sciences platform for clinical research. So far this year, 31 Chinese issuers have raised $12.3 billion in US IPOs, more than all of last year, representing roughly 15% of the US IPO market by deal count and proceeds.īacked by Alibaba Health, LinkDoc Technology provides a platform that structures cancer patient data to enable precision medicine and personalized care. Days after DiDi Global's ( DIDI) $4.4 billion US IPO, the regulator announced that it was pulling DiDi's app from the app store until it came under compliance with certain data security requirements, causing the stock to crash. The news comes amid China's latest crackdown of its domestic internet companies, which has most recently focused on US listings. On Wednesday, LinkDoc filed an amendment where it added risks related to China's new capital markets regulation and oversight, which had been issued by the country's regulator the day before. Chinabased linkdoc us ipotimes software Not all coins provided by Apex. It had filed to raise $200 million by offering 10.8 million shares at a price range of $17.50 to $19.50. Insiders and anchor investors had indicated an interest in buying 58% of the deal. #DIDI CHINABASED XIMALAYA LINKDOC US IPOTIMES SOFTWARE# reported that Beijing was pressing audio platform Ximalaya to drop U.S. In fact, three companies had pulled out recently. The company had been expected to price its IPO on Thursday night. Namely Keep (a popular fitness app in China), LinkDoc Technology (A Chinese medical data solution provider) and Ximalaya (China’s largest podcasting platform). To go one step further, Ximalaya has also stated its intention to list on Hong Kong instead. Why is the Chinese communist party doing. #DIDI CHINABASED XIMALAYA LINKDOC US IPOTIMES SOFTWARE#.
0 Comments
Leave a Reply. |